HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[123I]Epidepride neuroimaging of dopamine D2/D3 receptor in chronic MK-801-induced rat schizophrenia model.

AbstractPURPOSE:
[(123)I]Epidepride is a radio-tracer with very high affinity for dopamine D(2)/D(3) receptors in brain. The importance of alteration in dopamine D(2)/D(3) receptor binding condition has been wildly verified in schizophrenia. In the present study we set up a rat schizophrenia model by chronic injection of a non-competitive NMDA receptor antagonist, MK-801, to examine if [(123)I]epidepride could be used to evaluate the alterations of dopamine D(2)/D(3) receptor binding condition in specific brain regions.
METHOD:
Rats were given repeated injection of MK-801 (dissolved in saline, 0.3mg/kg) or saline for 1month. Afterwards, total distance traveled (cm) and social interaction changes were recorded. Radiochemical purity of [(123)I]epidepride was analyzed by Radio-Thin-Layer Chromatography (chloroform: methanol, 9:1, v/v) and [(123)I]epidepride neuroimages were obtained by ex vivo autoradiography and small animal SPECT/CT. Data obtained were then analyzed to determine the changes of specific binding ratio.
RESULT:
Chronic MK-801 treatment for a month caused significantly increased local motor activity and induced an inhibition of social interaction. As shown in [(123)I]epidepride ex vivo autoradiographs, MK-801 induced a decrease of specific binding ratio in the striatum (24.01%), hypothalamus (35.43%), midbrain (41.73%) and substantia nigra (37.93%). In addition, [(123)I]epidepride small animal SPECT/CT neuroimaging was performed in the striatum and midbrain. There were statistically significant decreases in specific binding ratio in both the striatum (P<.01) and midbrain (P<.05) between the saline and MK-801 group.
CONCLUSION:
These results suggest that [(123)I]epidepride is a useful radio-tracer to reveal the alterations of dopamine D(2)/D(3) receptor binding in a rat schizophrenia model and is also helpful to evaluate therapeutic effects of schizophrenia in the future.
AuthorsYuan-Ruei Huang, Jun-Ming Shih, Kang-Wei Chang, Chieh Huang, Yu-Lung Wu, Chia-Chieh Chen
JournalNuclear medicine and biology (Nucl Med Biol) Vol. 39 Issue 6 Pg. 826-32 (Aug 2012) ISSN: 1872-9614 [Electronic] United States
PMID22464847 (Publication Type: Journal Article)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Benzamides
  • Iodine Radioisotopes
  • Pyrrolidines
  • Receptors, Dopamine D2
  • Receptors, Dopamine D3
  • epidepride
  • Dizocilpine Maleate
  • Tyrosine 3-Monooxygenase
Topics
  • Animals
  • Behavior, Animal (drug effects)
  • Benzamides
  • Chronic Disease
  • Disease Models, Animal
  • Dizocilpine Maleate (pharmacology)
  • Iodine Radioisotopes
  • Male
  • Multimodal Imaging
  • Neostriatum (diagnostic imaging, drug effects, metabolism)
  • Neuroimaging (methods)
  • Positron-Emission Tomography
  • Pyrrolidines
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Dopamine D2 (analysis, metabolism)
  • Receptors, Dopamine D3 (analysis, metabolism)
  • Schizophrenia (chemically induced, diagnosis, diagnostic imaging, metabolism)
  • Tomography, X-Ray Computed
  • Tyrosine 3-Monooxygenase (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: